Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies
COVID-19 (SARS-CoV-2) disease severity and stages varies from asymptomatic, mild flu-like symptoms, moderate, severe, critical, and chronic disease. COVID-19 disease progression include lymphopenia, elevated proinflammatory cytokines and chemokines, accumulation of macrophages and neutrophils in lun...
Main Author: | Ricke, Darrell O. |
---|---|
Other Authors: | Lincoln Laboratory |
Format: | Article |
Published: |
Frontiers Media
2021
|
Online Access: | https://hdl.handle.net/1721.1/130232 |
Similar Items
-
Evolving understanding of antibody-dependent enhancement (ADE) of SARS-CoV-2
by: Yalong Yang, et al.
Published: (2022-10-01) -
Antibody-dependent enhancement (ADE) of SARS-CoV-2 pseudoviral infection requires FcγRIIB and virus-antibody complex with bivalent interaction
by: Shuang Wang, et al.
Published: (2022-03-01) -
Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19
by: Kumaragurubaran Karthik, et al.
Published: (2020-12-01) -
Antibody-Dependent Enhancement with a Focus on SARS-CoV-2 and Anti-Glycan Antibodies
by: Marina M. Ziganshina, et al.
Published: (2023-07-01) -
Theoretical Explanation for the Rarity of Antibody-Dependent Enhancement of Infection (ADE) in COVID-19
by: Anna E. Boldova, et al.
Published: (2022-09-01)